• DOI:10.1016/S0140-6736(95)92654-2
Corpus ID: 44624033

Treatment of HIV-associated Kaposi's sarcoma with paclitaxel

@article{Saville1995TreatmentOH,
  title={Treatment of HIV-associated Kaposi's sarcoma with paclitaxel},
  author={M. W. Saville and J. Lietzau and J. Pluda and W. Wilson and I. Feuerstein},
  journal={The Lancet},
  year={1995},
  volume={346},
  pages={26-28}
}

M. W. Saville, J. Lietzau, +2 authors I. Feuerstein

Published 1995

Medicine

The Lancet

We investigated whether paclitaxel was active in AIDS-associated Kaposi's sarcoma. We gave 135 mg/m2 intravenously over 3 hours every 21 days. Follow-up is available on the first 20 patients, most of whom had advanced Kaposi's sarcoma and severe immunocompromise. Neutropenia was the most frequent dose-limiting toxic effect; novel toxic effects included late fevers, rash, and eosinophilia. Creatinine increased in 2 patients and 1 patient had cardiomyopathy. There were 13 partial responses (65… CONTINUE READING

View on Elsevier

zenodo.org

Save to Library

Create Alert

Cite

Launch Research Feed